CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content.
Adult
Aged
Animals
Apoptosis Regulatory Proteins
Biomarkers
Chemical and Drug Induced Liver Injury
/ complications
Cytokines
/ metabolism
Disease Models, Animal
Disease Susceptibility
Female
Gene Expression
Hepatic Stellate Cells
/ metabolism
Humans
Immunity
Inflammation Mediators
/ metabolism
Liver Cirrhosis
/ etiology
Macrophages
/ immunology
Male
Mice
Middle Aged
Monocytes
/ immunology
Receptors, Scavenger
Scavenger Receptors, Class B
/ genetics
Young Adult
Apoptosis inhibitor of macrophages
Hepatic stellate cells
Macrophage
SMAD7
TGFB
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
18
02
2019
revised:
17
04
2019
accepted:
26
04
2019
pubmed:
12
5
2019
medline:
26
11
2019
entrez:
12
5
2019
Statut:
ppublish
Résumé
Chronic hepatic inflammation leads to liver fibrosis, which may progress to cirrhosis, a condition with high morbidity. Our aim was to assess the as yet unknown role of innate immunity protein CD5L in liver fibrosis. CD5L was measured by ELISA in plasma samples from cirrhotic (n = 63) and hepatitis (n = 39) patients, and healthy controls (n = 7), by immunohistochemistry in cirrhotic tissue (n = 12), and by quantitative RT-PCR in mouse liver cell subsets isolated by cell sorting. Recombinant CD5L (rCD5L) was administered into a murine model of CCl Cirrhotic patients showed elevated plasma CD5L concentrations as compared to patients with hepatitis and healthy controls (Mann-Whitney test p < 0·0001). Moreover, plasma CD5L correlated with disease progression, FIB4 fibrosis score (r:0·25, p < 0·0001) and tissue expression (r = 0·649; p = 0·022). Accordingly, CCl Our study identifies CD5L as a key pleiotropic inhibitor of chronic liver injury. FUND: Fundació Marató TV3, AGAUR and the ISCIII-EDRF.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic hepatic inflammation leads to liver fibrosis, which may progress to cirrhosis, a condition with high morbidity. Our aim was to assess the as yet unknown role of innate immunity protein CD5L in liver fibrosis.
METHODS
METHODS
CD5L was measured by ELISA in plasma samples from cirrhotic (n = 63) and hepatitis (n = 39) patients, and healthy controls (n = 7), by immunohistochemistry in cirrhotic tissue (n = 12), and by quantitative RT-PCR in mouse liver cell subsets isolated by cell sorting. Recombinant CD5L (rCD5L) was administered into a murine model of CCl
FINDINGS
RESULTS
Cirrhotic patients showed elevated plasma CD5L concentrations as compared to patients with hepatitis and healthy controls (Mann-Whitney test p < 0·0001). Moreover, plasma CD5L correlated with disease progression, FIB4 fibrosis score (r:0·25, p < 0·0001) and tissue expression (r = 0·649; p = 0·022). Accordingly, CCl
INTERPRETATION
CONCLUSIONS
Our study identifies CD5L as a key pleiotropic inhibitor of chronic liver injury. FUND: Fundació Marató TV3, AGAUR and the ISCIII-EDRF.
Identifiants
pubmed: 31076347
pii: S2352-3964(19)30291-9
doi: 10.1016/j.ebiom.2019.04.052
pmc: PMC6558273
pii:
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
Biomarkers
0
CD5L protein, human
0
Cytokines
0
Inflammation Mediators
0
Receptors, Scavenger
0
Scavenger Receptors, Class B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-524Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
Eur J Immunol. 1999 Apr;29(4):1086-93
pubmed: 10229074
J Biol Chem. 2001 Jun 22;276(25):22910-4
pubmed: 11294859
Nature. 2003 Oct 9;425(6958):577-84
pubmed: 14534577
Mol Cell Biol. 2004 May;24(10):4241-54
pubmed: 15121845
Kidney Int. 2004 Aug;66(2):605-13
pubmed: 15253713
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17813-8
pubmed: 15601766
J Clin Invest. 2005 Jan;115(1):56-65
pubmed: 15630444
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Cell Metab. 2005 Mar;1(3):201-13
pubmed: 16054063
Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):98-105
pubmed: 16265071
Hepatol Res. 2007 Aug;37(8):647-55
pubmed: 17559421
Biochem Soc Trans. 2007 Aug;35(Pt 4):661-4
pubmed: 17635115
Clin Chem. 2007 Oct;53(10):1792-9
pubmed: 17702858
Hepatology. 2009 Jul;50(1):261-74
pubmed: 19554540
BMC Cancer. 2009 Aug 05;9:271
pubmed: 19656391
Cell Metab. 2010 Jun 9;11(6):479-92
pubmed: 20519120
PLoS One. 2010 Jun 10;5(6):e11049
pubmed: 20548789
Infect Immun. 2011 Apr;79(4):1526-35
pubmed: 21263022
Cancer Res. 2011 Aug 15;71(16):5488-99
pubmed: 21697282
Gut. 2013 Mar;62(3):452-60
pubmed: 22637703
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3186-95
pubmed: 23100531
Crit Rev Immunol. 2013;33(1):57-96
pubmed: 23627007
Hepat Mon. 2013 Jul 03;13(7):e8351
pubmed: 24066001
PLoS One. 2013 Nov 04;8(11):e79670
pubmed: 24223991
J Leukoc Biol. 2014 Mar;95(3):509-20
pubmed: 24295828
Gut. 2014 Nov;63(11):1782-92
pubmed: 24415562
Hepatology. 2014 Mar;59(3):1060-72
pubmed: 24481979
BMC Gastroenterol. 2014 Feb 13;14:27
pubmed: 24524410
PLoS One. 2014 Oct 10;9(10):e109123
pubmed: 25302503
Autophagy. 2015;11(3):487-502
pubmed: 25713983
J Hepatol. 2015 Sep;63(3):670-8
pubmed: 25908269
J Leukoc Biol. 2015 Aug;98(2):173-84
pubmed: 26048980
Cell. 2015 Dec 3;163(6):1413-27
pubmed: 26607793
Exp Eye Res. 2017 Feb;155:64-74
pubmed: 27989757
J Clin Invest. 2017 Jan 3;127(1):55-64
pubmed: 28045404
J Hepatol. 2017 May;66(5):1037-1046
pubmed: 28167322
Hepatology. 2017 Sep;66(3):953-968
pubmed: 28422322
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
Int J Mol Sci. 2017 Dec 23;19(1):null
pubmed: 29295498
FASEB J. 2018 Jul;32(7):3878-3891
pubmed: 29465313
Front Immunol. 2018 Mar 12;9:480
pubmed: 29593730
Front Immunol. 2018 Apr 23;9:798
pubmed: 29740435
Nature. 1977 Apr 7;266(5602):550-2
pubmed: 558524
FEBS Lett. 1997 Feb 10;403(1):57-60
pubmed: 9038360
J Hepatol. 1999 Jan;30(1):77-87
pubmed: 9927153